

1 **CONTINUOUS CIRCULATION OF DENV-3 GENOTYPE 3 IN DELHI : A SINGLE**
2 **HOSPITAL BASED SURVEILLANCE STUDY**

3 Abhishek Padhi¹, Ekta Gupta¹, Gaurav Singh¹, Shama Parveen², Arshi Islam², Bansidhar
4 Tarai³

5 ¹ Department Of Clinical Virology, Institute Of Liver And Biliary Sciences, New Delhi

6 ² Centre For Interdisciplinary Research In Basic Sciences, Jamia Millia Islamia, New Delhi

7 ³ Department Of Microbiology And Infection Control, Max Superspeciality Hospital, Saket,
8 New Delhi

9

10 **CORRESPONDING AUTHOR**

11 Dr. Ekta Gupta

12 Professor and Head

13 Department Of Clinical Virology,

14 Institute Of Liver And Biliary Sciences, New Delhi

15 Email ID : ektagaurisha@gmail.com

16

17 **ABSTRACT**

18 **BACKGROUND**

19 Delhi is hyperendemic for dengue virus (DENV) where all the four DENV have been
20 previously reported. A constant vigilance of circulating dengue virus serotypes is important
21 in surveillance, since the introduction of a new variant to areas affected by pre-existing
22 serotypes constitutes a risk factor for DHF and Dengue Shock Syndrome.

23

24 **OBJECTIVES**

25 This retrospective study was carried out with an objective to determine the circulating
26 serotype and genotype of Dengue virus in acute phase blood samples of patients who
27 reported to a tertiary liver care hospital in New Delhi during the last two years (2017 – 2018).

28

29 METHODS

30 The data of clinician-initiated testing for dengue NS1 antigen was searched in the
31 institutional hospital information system. The serum sample of dengue NS1 antigen positive
32 cases confirmed by ELISA (PANBIO, Gyeonggi-do, ROK) and a fever duration of less than
33 5 days were retrieved from the laboratory archive. The dengue virus serotyping on these
34 sample were carried out by reverse transcriptase PCR. Sequencing and phylogenetic analysis
35 was done for the capsid-pre membrane (CPrM) region to determine the genotype.

36

37 RESULTS

38 A total of 440 acute-phase samples were received. Twenty one(4.77%) were positive
39 for dengue NS1 antigen with a mean age of 35.1 years and male to female ratio of
40 1.1:1. Eight cases (38.09%) were positive by Dengue RT-PCR and all belonged to DENV-3
41 serotypes. Phylogenetic tree analysis revealed DENV-3 clustered to genotype III with 100%
42 homology with 2008 Indian subcontinent strain.

43

44 CONCLUSION

45 This study revealed that the present circulating dengue virus serotype in Delhi is DENV-3
46 genotype III. It is similar to previously isolated 2008 Indian subcontinent strain suggesting
47 neither any change in serotype nor any further evolution of DENV-3. That explains the
48 present relatively stable dengue endemicity in Delhi NCR.

49 Key words : Dengue, DENV 3, Genotype 3, Surveillance

50 **INTRODUCTION**

51 Dengue is a vector borne acute arboviral infection widely prevalent in the tropics and sub
52 tropics. According to the World Health Organization (WHO) estimates, 3.6 billion people
53 reside in dengue endemic areas and 70 % of the actual burden is in Asia (1)(2).
54 Symptoms of dengue infection is wide ranging from subclinical disease to severe flu like
55 symptoms, and some people develop severe dengue associated with number of complications
56 such as severe bleeding, organ impairment and/or plasma leakage. Over the past two decades
57 the burden of dengue cases has increased almost 15 folds (1).

58 Dengue infection is caused by a virus belonging to the family *Flaviviridae*, genus *Flavivirus*
59 and consists of a single stranded positive sense RNA about 11 kb as its genome and encodes
60 for three structural {capsid (C), pre-membrane (prM) and envelope (E)} and 7 non-structural
61 proteins (3) . Dengue virus (DENV) can be classified into four antigenically distinct
62 serotypes (DENV-1, DENV-2, DENV-3, DENV-4) based on sequence diversity and each
63 serotype is further grouped into various genotypes (4).

64 A lifelong immunity is attained after infection with a particular serotype and a cross
65 protective immunity against other serotypes for a short period of time (5). Secondary
66 infection by a different serotype is associated with severe dengue probably due to antibody-
67 dependent enhancement (ADE) resulting in high viremia (6) (7).

68 Delhi is hyperendemic for DENV with co-circulation of all the four dengue serotypes (8) .
69 Delhi has witnessed a number of dengue epidemics in the past two decades due to rapid
70 boom in urbanization, monsoon influenced subtropical climate, water storage practices and
71 use of water coolers. These factors provide the mosquito vector *Aedes aegypti* a favourable
72 environment to thrive and transmit DENV amongst the human population which at times

73 gives rise to major outbreaks depending upon the circulating serotype and genotype of DENV
74 (9) (10).

75 In the absence of an effective vaccine, virological surveillance and development of effective,
76 locally adapted control programmes are the two most important arms in the prevention of
77 dengue infection. Hence, there is a need of continuous monitoring of the circulating DENV
78 type in a given population to develop such locally adapted control programmes. Furthermore
79 most studies focus on the circulating serotypes during epidemics and the studies on
80 circulating strains during the interepidemic periods are neglected and there can be significant
81 variations for which public health systems are unprepared (11).

82 We carried out the present study targeting the *CprM* gene junction to elucidate the molecular
83 epidemiology of the circulating strain of DENV in the population of Delhi post 2015 dengue
84 epidemic.

85 **MATERIAL AND METHODS**

86 *Patient selection and specimen collection*

87 This was a retrospective study carried out from January 2017 to December 2018 in a tertiary
88 care liver hospital in New Delhi, India. All consecutive patients with signs and symptoms
89 (according to WHO guidelines) suggestive of DENV infections visiting the OPD or admitted
90 in IPD were tested for DENV infection (12) . Plasma was separated from blood samples and
91 stored in the virology repository at -80 °C till further testing.

92 *DENV diagnosis*

93 Diagnosis of DENV was done with Dengue NS1 Ag (PANBIO ,Gyeonggi-do, ROK) if the
94 sample was collected within the first 5 days of onset of clinical symptoms, and with Dengue

95 IgM capture ELISA (PANBIO ,Gyeonggi-do, ROK) if the sample was collected after 5 days
96 of onset of clinical symptoms.

97 *RNA extraction and cDNA synthesis*

98 All the DENV NS1 Ag-positive cases were further processed for RNA extraction using
99 QIAamp Viral Mini kit (Qiagen,GmbH, Germany) according to the manufactures'
100 instructions. The extracted viral RNA was reverse transcribed to cDNA using Quantitect
101 reverse transcriptase kit (QIAGEN, GmbH Germany) according to manufacturer's
102 instructions.

103 *Detection of DENV by RT-PCR*

104 The cDNA was then amplified in the external round of RT-PCR using dengue virus
105 consensus primers (D1: 5' TCAATATGCTGAAACGCGCGAGAAACC G 3'; D2: 5'
106 TTGCACCAACAGTCAATGTCT TCA GGT TC 3') in 25 µl reaction volume. The DNA
107 product obtained was of 511 bp.

108 Subsequent amplification of cDNA was carried out with the dengue virus consensus forward
109 primer (D1) and four dengue serotype-specific reverse primers (TS 1: 5'
110 CGTCTCAGTGATCCGGGGA 3'; TS 2: 5' CGCCACAAGGGCCATGAACAG 3'; TS 3:
111 5' TAACATCAT- CATGAGACAGAGC 3'; TS 4: 5'CTCTGTTGTCTTAAACAAGAGA
112 3') as described by Lanciotti *et al* ⁽¹³⁾, but all the 4 serotype-specific primers were added in a
113 single reaction mixture. A 1 : 20 dilution of the external PCR product was used in the nested
114 PCR reaction. Dengue virus serotypes were identified by the size of the resulting DNA bands
115 (DENV 1–482 bp, DENV 2–119 bp, DENV 3–290 bp, DENV 4–392 bp). Amplicons were
116 resolved on 2% agarose gel and visualized with ethidium bromide in UV light by using a gel
117 documentation system (Wealtec, USA).

118 *DNA Sequencing*

119 PCR amplicons were gel-purified using QIAquick gel extraction kit (QIAGEN, GmbH
120 Germany) as per manufacturer's instructions. Purified amplicons were subjected to Sanger
121 sequencing using ABI 3730 DNA analyzer (ThermoFisher Scientific, MA, Waltham).

122 *Phylogenetic analysis*

123 Identity of the obtained sequences were confirmed by BLAST tool available at NCBI
124 (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>). Both forward and reverse sequences were manually
125 aligned and edited to resolve the nucleotide ambiguities and to obtain consensus sequence
126 using GeneDoc v.2.7 (<http://genedoc.software.informer.com/2.7/>) and BioEdit v.7.2
127 (<http://bioedit.software.informer.com/7.2/>). The study sequences were aligned with other
128 available sequences retrieved from Genbank using CLUSTAL X2 ([http://](http://www.clustal.org/clustal2/)
129 www.clustal.org/clustal2/) achieved in BioEdit v.7.2 ([http://bioedit.](http://bioedit.software.informer.com/7.2/)
130 [software.informer.com/7.2/](http://bioedit.software.informer.com/7.2/)). All the new sequences of DENV-3 genome were submitted to
131 Genbank.

132 The phylogenetic tree was constructed for the DENV-3 sequences by Maximum Likelihood
133 method using algorithms implemented in MEGA6 v.6.06 software. Genetic distances were
134 calculated using Tamura-Nei model of nucleotide substitution. The robustness of the tree was
135 assessed with 1000 bootstrap replicates.

136 **ETHICS**

137 The study was approved by the Institutional ethics committee (IEC) of Institute of Liver and
138 Biliary Sciences (ILBS) and patient consent form was waived off because of the use of
139 leftover clinical samples sent to virology laboratory for routine diagnosis for DENV.

140

141

142 **RESULTS**

143 A total of 440 acute-phase samples were received. Twenty one(4.77%) were positive
144 for dengue NS1 antigen with a mean age of 35.1 years and male to female ratio of
145 1.1:1. Eight cases (38.09%) were positive by Dengue RT-PCR and all belonged to DENV-3
146 serotypes. No case of concomitant infection with more than one serotype was observed. In
147 cases where NS1 antigen was positive but RT-PCR was negative, duration of fever was 5
148 days, as by this time viremia declines and only NS1 antigen persists till IgM antibodies are
149 formed.

150 *DNA sequence analysis*

151 The CprM region of the DENV-3 genome was sequenced for 8 positive samples. The
152 samples were sequenced in both forward and reverse direction. All the obtained DENV-3
153 sequences were confirmed by BLAST. These sequences were submitted in Genbank database
154 and accession number of the same are awaited.

155 *Phylogenetic analysis*

156 Phylogenetic analysis of DENV-3 serotype was carried out for the present investigation. The
157 H87 strain of genotype V of DENV-3 (GenBank Accession number M93130) was used as the
158 proto- type strain. The aligned region was 240bp that corresponds to 131 to 370bp of the
159 CprM region of full genome the prototype strain. Eighty sequences (8 studied and 72 other
160 sequences of different genotypes of DENV-3 (GenBank) were aligned to construct Maximum

161 Likelihood tree. Phylogenetic analysis clustered all the studied sequences with the genotype
162 III (Indian subcontinent).

163


164

165

166

167

168



Maximum likelihood phylogenetic tree of DENV-3 strains. The study sequences are marked by the symbol Δ . Bootstrap values are represented by the number on nodes generated by 1000 replications. The strains used to construct the tree are represented by the strain name, followed by country/region and year of isolation/submission of strain. The study sequences clustered with Genotype III (Indian subcontinent).

170 **DISCUSSION**

171 Delhi, the capital of India is known to be hyperendemic for DENV infection due to the
172 circulation of all the four serotypes in the population (10). In the past two decades Delhi has
173 witnessed several outbreaks and epidemics of DENV infection. Dense human population,
174 rapid urbanization, increasing globalization and the tropical climatic conditions have
175 contributed towards the frequent outbreaks of DENV infection in Delhi. Hence, a continuous
176 sero-surveillance of the circulating DENV strain is a necessity to prevent further epidemics
177 and help in the development of local control program (14) .

178 In the present study, molecular characterization of circulating DENV strains was carried out
179 targeting the *CprM* junction. Genotyping based on *CprM* junction is easier and economical
180 because of the utilisation of a single set of primer for both amplification and sequencing of
181 any of the four DENV serotypes (9).

182 A change in the circulation pattern of Dengue serotypes has been reported from Delhi in
183 terms of prevalent serotype. The DENV-2 serotype dominated the Dengue fever during 2003
184 to 2006 (15)(16) (17)(18)(19). DENV-3 emerged as a dominant serotype in the year 2003
185 which continued in circulation till 2006 (15). In addition, 2006 also reported the emergence
186 of DENV-1 in 30% of the cases (15) . Subsequently, the predominance of DENV-1 was
187 reported till 2010 . DENV-1 and DENV-2 serotypes co-circulated in almost equal proportions
188 in 2011 [8]. A switch in the prevailing serotype occurred again in 2012 due to co-dominant
189 circulation of DENV-2 and DENV- 3. DENV-2 dominated during 2012, 2013 and 2015
190 [8,15]. Subsequently, DENV-1 dominated in 2014 [16]. Further, during 2016 a change in the
191 circulating serotype occurred leading to dominance of DENV-3 in this region.

YEAR	DENV SEROTYPE	EPIDEMIC/ NON	REFERENCES
-------------	----------------------	----------------------	-------------------

		EPIDEMIC	
1996	2	Epidemic	Dar et al (20)
1997	1	Non epidemic	Vajpayee et al(21)
2003	1,2,3(Genotype III),4	Epidemic	Gupta et al (8)
2004	1	Non epidemic	Gupta et al(22)
2005	3(Genotype III)	Epidemic	Gupta et al(22)
2006	3(Genotype III)	Epidemic	Bharaj et al (23)
2007	3(Genotype III)	Non epidemic	Kukreti et al (15)
2008	1	Non epidemic	Chakravarti et al (24)
2010	1	Non epidemic	Gupta et al (25)
2011-2014	1,2,3(Genotype III)	Non epidemic	Afreen et al (26)
2015	2	Epidemic	Choudhary et al(27)
2016	3(Genotype III)	Non epidemic	Parveen et al(28)
2017-2018	3(Genotype III)	Non epidemic	Present study

192 Table 1 : Circulation of various dengue serotypes in Delhi

193

194 The most relevant finding of our study was the circulation of a single serotype, DENV-3
195 genotype III during 2017-2018 which was similar to the DENV-3 strain circulating in the
196 year 2016 (28). Similar studies from Pakistan also reported the circulation of DENV-3 during
197 2015 (29). Studied strains of DENV-3 were clustered in Genotype III (Indian subcontinent)
198 by phylogenetic analysis. The analysis also concluded that the DENV-3 study sequences

199 grouped with the strains from China (unpublished), Pakistan (30) and India (30) (31) (32) .

200 Furthermore DENV-3 serotype has been reported from different geographical regions

201 including India.

202 The oldest DENV-3 strain, Philippines 56, was classified as genotype I along with other

203 strains from the Philippines and Indonesia isolated over two decades, suggesting the

204 persistence of this genotype in the area for a long time.

205

206 It is evident that genotype III of DENV-3 circulates throughout the world, whereas other

207 genotypes are localized in particular geographic regions. This indicates a higher potential of

208 genotype III to spread and dominate in geographically diverse regions of the world. This

209 genotype has also been implicated in major dengue epidemics in several parts of Asia, Africa

210 and the Americas and has the potential to cause an international dengue pandemic (33).

211 Furthermore our study also shows that in the non-epidemic period usually one strain

212 circulates and co-circulation of multiple types with concurrent infection with more than one

213 serotype is not seen.

214 **CONCLUSION**

215 The findings of this study indicate continuous circulation of DENV-3, genotype III, since

216 2003 in Delhi. DENV-3, Genotype III has a potential to cause global pandemic which

217 warrants a continued surveillance to monitor its incursion and spread for effective control

218 measures before the onset of the next outbreak. Further studies to understand the host

219 adaptation mechanisms for vaccine implementation in our population are warranted .

220

221 **ACKNOWLEDGEMENT**

222 The authors would like to thank Mr. Piyush Bahuguna for his contribution in providing the
223 data for dengue virus infection for the year 2017-2018.

224 **CONFLICT OF INTEREST**

225 None

226 **FUNDING**

227 None

228

229

230

231

232 References :

233

- 234 1. Dengue and severe dengue [Internet]. [cited 2020 Mar 14]. Available from:
235 <https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue>
- 236 2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global
237 distribution and burden of dengue. *Nature*. 2013 Apr 25;496(7446):504–7.
- 238 3. Dengue infection | Nature Reviews Disease Primers [Internet]. [cited 2020 Mar 14].
239 Available from:
240 <https://www.nature.com/articles/nrdp201655?draft=collection&proof=true>
- 241 4. Chen R, Vasilakis N. Dengue — Quo tu et quo vadis? *Viruses*. 2011 Sep 1;3(9):1562–
242 608.
- 243 5. Gubler DJ. The Global Emergence/Resurgence of Arboviral Diseases As Public Health
244 Problems. *Archives of Medical Research*. 2002 Jul 1;33(4):330–42.
- 245 6. Guzman MG, Vazquez S. The Complexity of Antibody-Dependent Enhancement of
246 Dengue Virus Infection. *Viruses*. 2010 Dec 8;2(12):2649–62.
- 247 7. Grange L, Simon-Loriere E, Sakuntabhai A, Gresh L, Paul R, Harris E. Epidemiological
248 Risk Factors Associated with High Global Frequency of Inapparent Dengue Virus
249 Infections. *Front Immunol* [Internet]. 2014 Jun 11 [cited 2020 Mar 14];5. Available
250 from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052743/>
- 251 8. Dar L, Gupta E, Narang P, Broor S. Cocirculation of dengue serotypes, Delhi, India,
252 2003. *Emerging Infect Dis*. 2006 Feb;12(2):352–3.

- 253 9. Kukreti H, Mittal V, Chaudhary A, Rautela RS, Kumar M, Chauhan S, et al. Continued
254 persistence of a single genotype of dengue virus type-3 (DENV-3) in Delhi, India since
255 its re-emergence over the last decade. *J Microbiol Immunol Infect.* 2010 Feb;43(1):53–
256 61.
- 257 10. Gupta E, Dar L, Kapoor G, Broor S. The changing epidemiology of dengue in Delhi,
258 India. *Virology*. 2006 Nov 5;3:92.
- 259 11. Gupta E, Mohan S, Bajpai M, Choudhary A, Singh G. Circulation of Dengue virus-1
260 (DENV-1) serotype in Delhi, during 2010–11 after Dengue virus-3 (DENV-3)
261 predominance: A single centre hospital based study. :4.
- 262 12. Organization WH. Dengue guidelines for diagnosis, treatment, prevention and control :
263 new edition [Internet]. World Health Organization; 2009 [cited 2020 Mar 14]. Available
264 from: <https://apps.who.int/iris/handle/10665/44188>
- 265 13. Lanciotti RS, Calisher CH, Gubler DJ, Chang G-J, VORNDAMt AV. Rapid Detection
266 and Typing of Dengue Viruses from Clinical Samples by Using Reverse Transcriptase-
267 Polymerase Chain Reaction. *J CLIN MICROBIOL.* 1992;30:7.
- 268 14. Gore MM. Need for constant monitoring of dengue infections. *Indian J Med Res.* 2005
269 Jan;121(1):9–12.
- 270 15. Kukreti H, Chaudhary A, Rautela RS, Anand R, Mittal V, Chhabra M, et al. Emergence
271 of an independent lineage of dengue virus type 1 (DENV-1) and its co-circulation with
272 predominant DENV-3 during the 2006 dengue fever outbreak in Delhi. *Int J Infect Dis.*
273 2008 Sep;12(5):542–9.

- 274 16. Lanciotti RS, Calisher CH, Gubler DJ, Chang G-J, VORNDAMt AV. Rapid Detection
275 and Typing of Dengue Viruses from Clinical Samples by Using Reverse Transcriptase-
276 Polymerase Chain Reaction. *J CLIN MICROBIOL*. 1992;30:7.
- 277 17. Dash PK, Parida MM, Saxena P, Kumar M, Rai A, Pasha ST, et al. Emergence and
278 continued circulation of dengue-2 (genotype IV) virus strains in northern India. *J Med*
279 *Virol*. 2004 Oct;74(2):314–22.
- 280 18. Singh P, Mittal V, Rizvi MMA, Chhabra M, Sharma P, Rawat DS, et al. The first
281 dominant co-circulation of both dengue and chikungunya viruses during the post-
282 monsoon period of 2010 in Delhi, India. *Epidemiol Infect*. 2012 Jul;140(7):1337–42.
- 283 19. Singh UB, Maitra A, Broor S, Rai A, Pasha ST, Seth P. Partial nucleotide sequencing
284 and molecular evolution of epidemic causing Dengue 2 strains. *J Infect Dis*. 1999
285 Oct;180(4):959–65.
- 286 20. Dar L, Broor S, Sengupta S, Xess I, Seth P. The first major outbreak of dengue
287 hemorrhagic fever in Delhi, India. *Emerg Infect Dis*. 1999;5(4):589–90.
- 288 21. Vajpayee M, Mohankumar K, Wali JP, Dar L, Seth P, Broor S. Dengue virus infection
289 during post-epidemic period in Delhi, India. *Southeast Asian J Trop Med Public Health*.
290 1999 Sep;30(3):507–10.
- 291 22. Gupta E, Dar L, Kapoor G, Broor S. The changing epidemiology of dengue in Delhi,
292 India. *Virol J*. 2006 Nov 5;3:92.
- 293 23. Bharaj P, Chahar HS, Pandey A, Diddi K, Dar L, Guleria R, et al. Concurrent infections
294 by all four dengue virus serotypes during an outbreak of dengue in 2006 in Delhi, India.
295 *Virol J*. 2008 Jan 9;5:1.

- 296 24. Chakravarti A, Kumar A, Matlani M. Displacement of dengue virus type 3 and type 2
297 by dengue virus type 1 in Delhi during 2008. *Indian J Med Microbiol.* 2010
298 Dec;28(4):412.
- 299 25. Gupta E, Mohan S, Bajpai M, Choudhary A, Singh G. Circulation of Dengue virus-1
300 (DENV-1) serotype in Delhi, during 2010–11 after Dengue virus-3 (DENV-3)
301 predominance: A single centre hospital based study. :4.
- 302 26. Afreen N, Naqvi IH, Broor S, Ahmed A, Parveen S. Phylogenetic and Molecular Clock
303 Analysis of Dengue Serotype 1 and 3 from New Delhi, India. *PLoS ONE.*
304 2015;10(11):e0141628.
- 305 27. Choudhary MC, Gupta E, Sharma S, Hasnain N, Agarwala P. Genetic signatures
306 coupled with lineage shift characterise endemic evolution of Dengue virus serotype 2
307 during 2015 outbreak in Delhi, India. *Trop Med Int Health.* 2017 Jul;22(7):871–80.
- 308 28. Parveen N, Islam A, Tazeen A, Hisamuddin M, Abdullah M, Naqvi IH, et al.
309 Circulation of single serotype of Dengue Virus (DENV-3) in New Delhi, India during
310 2016: A change in the epidemiological trend. *Journal of Infection and Public Health.*
311 2019 Jan 1;12(1):49–56.
- 312 29. Suleman M, Faryal R, Alam MM, Khurshid A, Sharif S, Shaukat S, et al. Outbreak of
313 dengue virus type-3 in Malakand, Pakistan 2015; A laboratory perspective. *Acta Trop.*
314 2017 May;169:202–6.
- 315 30. Koo C, Nasir A, Hapuarachchi HC, Lee K-S, Hasan Z, Ng L-C, et al. Evolution and
316 heterogeneity of multiple serotypes of Dengue virus in Pakistan, 2006–2011. *Virology*
317 *Journal.* 2013 Sep 4;10(1):275.

- 318 31. Sharma S, Dash PK, Agarwal S, Shukla J, Parida MM, Rao PVL. Comparative
319 complete genome analysis of dengue virus type 3 circulating in India between 2003 and
320 2008. *J Gen Virol*. 2011 Jul;92(Pt 7):1595–600.
- 321 32. Dash PK, Parida MM, Saxena P, Abhyankar A, Singh C, Tewari K, et al. Reemergence
322 of dengue virus type-3 (subtype-III) in India: Implications for increased incidence of
323 DHF & DSS. *Virology*. 2006 Jul 6;3:55.
- 324 33. Messer WB, Gubler DJ, Harris E, Sivananthan K, de Silva AM. Emergence and Global
325 Spread of a Dengue Serotype 3, Subtype III Virus. *Emerg Infect Dis*. 2003
326 Jul;9(7):800–9.
- 327